3,690
edits
Obesity: Difference between revisions
no edit summary
No edit summary |
No edit summary |
||
| Line 41: | Line 41: | ||
Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252. | Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug;24(8):1553-1564. doi: 10.1111/dom.14725. Epub 2022 May 19. PMID: 35441470; PMCID: PMC9542252. | ||
[https://pubmed.ncbi.nlm.nih.gov/24708463/ A retrospective description of anesthetic medication dosing in overweight and obese children] | |||
[https://europepmc.org/article/med/28258392 Propofol clearance in morbidly obese children and adolescents] | [https://europepmc.org/article/med/28258392 Propofol clearance in morbidly obese children and adolescents] | ||